Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Saturday. The firm set a “sell” rating on the stock.

Separately, Dawson James assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They issued a “buy” rating and a $3.00 price target on the stock.

Tonix Pharmaceuticals Trading Up 5.3 %

NASDAQ:TNXP opened at $0.17 on Friday. The stock’s 50-day moving average is $0.28 and its two-hundred day moving average is $0.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The stock has a market cap of $14.24 million, a PE ratio of -0.02 and a beta of 2.21. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $3.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The company had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.95 million. As a group, equities research analysts forecast that Tonix Pharmaceuticals will post -3.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Sabby Management LLC bought a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals comprises approximately 0.5% of Sabby Management LLC’s investment portfolio, making the stock its 6th biggest position. Sabby Management LLC owned approximately 7.02% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.